Spotlight
Specialty
Partners
CME/CE
nmCRPC: Clinical Trial Data on AR Inhibitors
Shared insight on the SPARTAN, PROSPER, and ARAMIS studies with androgen receptor (AR) inhibitors in non-metastatic castration-resistant prostate cancer.
EP: 1.Breakthroughs in Imaging Modalities for Prostate Cancer
EP: 2.Prostate Cancer Imaging: Unmet Needs and Knowledge Gaps
EP: 3.Recent Progress in the Prostate Cancer Treatment Landscape
EP: 4.Key Unmet Needs in Prostate Cancer Management
EP: 5.Goals of Treatment for Non-metastatic Castration-Resistant Prostate Cancer
Now Viewing
EP: 6.nmCRPC: Clinical Trial Data on AR Inhibitors
EP: 7.AR Inhibitors in nmCRPC: Real-World Data
EP: 8.Importance of Quality of Life When Choosing Therapy for nmCRPC
EP: 9.Non-metastatic Castration-Resistant Prostate Cancer: Patient Monitoring Strategies
EP: 10.Optimizing Care for Patients With Non-metastatic CRPC
EP: 11.Treatment Goals for Patients With Metastatic Hormone-Sensitive Prostate Cancer
EP: 12.Factors in Selecting Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer
EP: 13.mHSPC: Use of Triplet Therapy
EP: 14.Metastatic Hormone-Sensitive Prostate Cancer: Data From ARASENS and ARANOTE
EP: 15.Metastatic Hormone-Sensitive Prostate Cancer: Data From ENZAMET and ARCHES
EP: 16.Metastatic Hormone-Sensitive Prostate Cancer: Data from TITAN and PEACE-1
EP: 17.Educating Patients on Treatment Options in Metastatic HSPC
EP: 18.Novel Treatment Modalities in Metastatic Hormone-Sensitive Prostate Cancer
EP: 19.Overview of the Metastatic Castration-Resistant Prostate Cancer Treatment Paradigm
EP: 20.Metastatic CRPC: Advent of PARP Inhibitors
EP: 21.Practical Application of PARP Inhibitors in Metastatic CRPC
EP: 22.IO Therapy in mCRPC and Clinical Pearls
Related Videos
Related Content
